4 Other than being on GLP-1s, higher risk patients include: those in the dose-escalation phase and those with upper GI symptoms (eg, nausea, vomiting, dyspepsia, abdominal distension, and abdominal discomfort/pain). 4 And obviously, other high-risk group includes patients with comorbidities associated with delayed gastric emptying (eg, poorly controlled diabetes, Parkinsons disease, bowel dysmotility) as well as those on other drugs that slow gastric emptying (eg, opioids, tricyclic antidepressants, marijuana, alcohol)
Eli Lilly TRIUMPH-4 topline, December 11, 2025 (Phase 3)
Ghrelin receptor agonists amplify that signal and add their own independent GH-releasing pulse
But there are still a few steps you should take to make sure the process is safe and smooth